Research Report on China's Biopharmaceutical Industry, 2010-2012

Date: December 22, 2010
Pages: 70
Price:
US$ 2,200.00
Publisher: China Research and Intelligence Co., Ltd.
Language:
Report type: Strategic Report
Delivery: E-mail Delivery (PDF), Online Subscription, Hard Copy Mail Delivery
ID: M0D6B6E7800EN
Leaflet:

Download PDF Leaflet

Research Report on China's Biopharmaceutical Industry, 2010-2012
In China, biological products for human use include bacterial vaccines (including toxoid), viral vaccines, antitoxin and immune serum, blood products, cytokines, in vivo and in vitro diagnostic products and other active agents (including toxins, antigen, allergens, recombinant DNA products, etc.). In China, the veterinary vaccine belongs to not the biopharmaceutical industry but the realm of the veterinary drug. The ""biopharmaceutical"" in this report only refers to the biological product for human use.

China's biological product industry is an emerging industry only with a 20-year history. The sales revenue of China's biopharmaceutical industry in 2009 was about CNY 89 billion (about USD13 billion), accounting for less than 10% of the total sales revenue of the pharmaceutical industry. But its development potential is enormous, and its share in the pharmaceutical industry is on the rise.

Under the influence of such contributing factors as the rapid growth of China's economy, the increasing residents' income as well as their knowledge and demands for biological medicines, China's pharmaceutical industry market is gradually expanding with the rising status in the national economy and becoming a potential industry in the eyes of investors.

With the continuing advancement of medical standards and people awareness of the disease treatment, there are more treatment methods of non-conservative operations, promoting the development of the blood product market. Currently, there are over 20 species of conventional blood products clinically, belonging to such three subgroups as human serum albumins, immune globulins, and clotting factors.

As the consuming capacity of Chinese consumers and their awareness of protecting health enhancing, Chinese demands for vaccines for human use are growing and the market scale is expanding.

As consumers are deepening their understanding of types and efficacies of biopharmaceuticals, in vitro diagnostic reagent products are slowly approaching the families, and genetic engineering drugs and antibody drugs are also gradually replacing part of chemical carcinoma drugs with strong side effects, thus greatly benefiting the treatment of cancer patients.

In 2009, the export value of China's biopharmaceuticals reached USD 1.45 billion , increasing by 60.22% over 2008; the import value was USD 1.02 billion, increasing by 31.80% over 2008. Relative to other products produced in China, China's biopharmaceutical products occupy a very small share in the international market. However, the status of low market concentration of China's pharmaceutical industry and backward technology has created conditions for foreign companies to settle in China. The international biopharmaceutical enterprises have found the opportunities in Chinese market and are gradually further exploiting Chinese market.

Following and more information can be acquired from this report:
  • Development of China's Biopharmaceutical Industry
  • Development of China's Biopharmaceutical Sub-industries
  • Market Competition of China's Biopharmaceutical Industry
  • Import and Export of China's Biopharmaceutical Industry
  • Major Enterprises in China's Biopharmaceutical Industry and Their Operations
  • Prediction on Development Trend of China's Biopharmaceutical Industry
Following people are suggested to buy this report:
  • Biopharmaceutical Manufacturing Enterprises
  • Biopharmaceutical Trade Enterprises
  • Research Institutions Focusing on China's Biopharmaceutical Industry
  • Investors Focusing on China's Biopharmaceutical Industry
1 OVERVIEW OF CHINA'S BIOPHARMACEUTICAL INDUSTRY, 2009-2012

1.1 Development of the Biopharmaceutical Industry
  1.1.1 Definition of the Biopharmaceutical Industry
  1.1.2 Features of the Biopharmaceutical Industry
  1.1.3 Status Quo of China's Biopharmaceutical Industry
1.2 Analysis and Prediction on the Supply of China's Biopharmaceutical Industry, 2009-2012
  1.2.1 Analysis on Total Supply
  1.2.2 Analysis on Supply Structure
  1.2.3 Supply Prediction, 2011-2012
1.3 Analysis and Prediction on the Demand of China's Biopharmaceutical Industry, 2009-2012
  1.3.1 Analysis on Total Demand
  1.3.2 Analysis on Demand Structure
  1.3.3 Demand Prediction, 2011-2012
1.4 Analysis and Prediction on Import and Export of China's Biopharmaceutical Industry, 2009-2012
  1.4.1 Import Analysis on China's Biopharmaceutical Industry
  1.4.2 Export Analysis on China's Biopharmaceutical Industry
  1.4.3 Prediction on Import and Export of the Biopharmaceutical Industry

2 ANALYSIS AND PREDICTION ON COMPETITION IN CHINA'S BIOPHARMACEUTICAL INDUSTRY, 2009-2012

2.1 Analysis and Prediction on Competition Characteristics in the Industry
  2.1.1 Higher Enterprise Concentration
  2.1.2 Strengthening Supervision
  2.1.3 Analysis on Competition between Foreign Drugs Giants and Chinese Enterprises
2.2 Analysis on Competition Pattern of the Industry
  2.2.1 Potential New Entrants of the Industry
  2.2.2 Competition among Existing Competitors
  2.2.3 Suppliers' Bargaining Power
  2.2.4 Buyers' Bargaining Power
  2.2.5 Threat of Substitute Products
2.3 Analysis and Prediction on M&A in China's Biopharmaceutical Industry
2.4 Analysis and Prediction on Development of Technical Know-how

3 ANALYSIS ON SUB-INDUSTRIES OF CHINA'S BIOPHARMACEUTICAL INDUSTRY, 2009-2012

3.1 Blood Products
  3.1.1 Market Profile of Blood Products
  3.1.2 Analysis and Prediction on the Blood Product Market
3.2 Vaccine
  3.2.1 Overview of the Vaccine Market
  3.2.2 Analysis and Prediction on the Vaccine Market
3.3 Diagnostic Reagents
  3.3.1 Market Profile of China's Diagnostic Reagent Market
  3.3.2 Development Trend of the Diagnostic Reagent Market
3.4 Gene Recombinant Drugs
  3.4.1Market Status of China's Gene Recombinant Drugs
  3.4.2 Development Trend of China's Gene Recombinant Drug Market

4 REGIONAL ANALYSIS ON CHINA'S BIOPHARMACEUTICAL INDUSTRY, 2009-2012

4.1 Overall Analysis and Prediction on Area Distributions of the Industry
  4.1.1 Analysis and Prediction on Area Distributions of the Industry Scale Indicators
  4.1.2 Analysis and Prediction on Area Distributions of the Industry Performance Indicators
4.2 Shandong Province
  4.2.1 Overview of the Biopharmaceutical Industry in Shandong Province
  4.2.2 Analysis on Operations of the Biopharmaceutical Industry in Shandong Province
  4.2.3 Prediction on Development Trend of the Biopharmaceutical Industry in Shandong Province
4.3 Jiangsu Province
4.4 Shanghai

5 ANALYSIS ON MAJOR ENTERPRISES IN CHINA'S BIOPHARMACEUTICAL INDUSTRY, 2009-2010

5.1 Hualan Biological Engineering Co., Ltd.
  5.1.1 Company Profile
  5.1.2 Operations
  5.1.3 Development Strategies
5.2 Shanghai Kehua Boi-engineering Co., Ltd.
  5.2.1 Company Profile
  5.2.2 Operations
  5.2.3 Development Strategies
5.3 Beijing Tiantan Biological Products Co., Ltd.
5.4 Beijing SL Pharmaceutical Co., Ltd.
5.5 DaAn Gene Co., Ltd.
5.6 Shanghai Laishi Blood products CO., Ltd.
5.7 Tonghua Dongbao Pharmaceutical Co., Ltd.

6 ANALYSIS ON DEVELOPMENT RISKS IN CHINA'S BIOPHARMACEUTICAL INDUSTRY, 2011-2012

6.1 Analysis on Economic Environment Risks
  6.1.1 Influence of International Economic Environment on the Industry
  6.1.2 Influence of China's Macroeconomy on the Industry
  6.1.3 Influence of Exchange Rate Changes on the Industry
6.2 Analysis on Policy Risks
  6.2.1 Influence of Industrial Policies
  6.2.2 Influence of Environmental Protection Policies
6.3 Analysis on Market Risks
  6.3.1 Risks of Market Supply and Demand
  6.3.2 Price Risks
  6.3.3 Industry Competition

7 ANALYSIS ON INVESTMENT AND DEVELOPMENT IN CHINA'S BIOPHARMACEUTICAL INDUSTRY, 2011-2012

7.1 Investment Opportunities in the Biopharmaceutical Industry
  7.1.1 Overall Investment Opportunities
  7.1.2 Investment Opportunities of Sub-industries
  7.1.3 Regional Investment Opportunities
7.2 Prediction on Investment Opportunities of Related Industries of China's Biopharmaceutical Industry Chain
  7.2.1 Investment Opportunities of the Pharmaceutical Commerce
  7.2.2 Investment Opportunities of the Medical Appliance Industry
7.3 Proposals for Investment and Development of China's Biopharmaceutical Industry

SELECTED CHARTS

Chart Analysis on Market Scale of China's Biopharmaceutical Industry, 2005-2010
Chart Prediction on Market Scale of China's Biopharmaceutical Industry, 2011-2015
Chart Market Scale of China's Blood Products, 2005-2010
Chart Market Scale of China's Vaccines for Human Use, 2005-2010
Chart Market Scale of China's Diagnostic Reagents, 2005-2010
Chart Regulatory Policies of the Chinese Government for the Biopharmaceutical Industry
Chart Production Capacity of H1N1 Vaccines in China's Major Vaccine Enterprises, 2010
Chart Market Shares of China's In-vitro Diagnostic Reagents, 2010
Chart Analysis on Scales of Major Genomic Medicine Markets in the world, 2004-2010
Chart Operations of the Biopharmaceutical Industry in Shandong Province
Chart Analysis on Import and Export of China's Biopharmaceutical Industry, 2005-2010
Chart Price Trend of China's Albumin Products
Chart Operations of Hualan Biological Engineering Co., Ltd., 2005-2010
Skip to top


Ask Your Question

Research Report on China's Biopharmaceutical Industry, 2010-2012
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: